Final Height Outcome in Girls with Turner Syndrome Treated with Growth Hormone and Low Dose Estrogen

Abstract

We reported final height data of collected 28 cases with Turner Syndrome (TS) were confirmed with chromosomal analysis during height growth hormone therapy and late estrogen therapy. Participants were allocated into one of 3 Groups, Group A: 11 patients aged between 15-18 years-old, group B: 10 patients aged between 10 -15 years-old, group C: 7 patients younger than 10 years-old. In contrast to the duration of growth hormone & presentation, group B showed a significantly higher final height mean (147.5 ±6.5 cm) the best result well be obtained in group B treated with high doses of growth hormone for longer period. Records of female patients with TS confirmed by karyotype analysis were examined; 15 patients had the typical Turner karyotype and 13 patients had a karyotype indicative of one of the TS variations. Four of the sixteen individuals in variations lacked clinical stigmata associated with Turner Syndrome; the other nine had one or more of the usual clinical stigmata associated with TS. Two cases who had a complicated mosaic karyotype also possessed a Y chromosome. Three patients in group of classics had coarctation of the aorta and one patient in had variants of TS. 5 patients had primary hypothyroidism and received levothyroxine. two pts has hyperthyroidism. In Turner syndrome (TS), Growth Hormone (GH) treatment promotes growth and adult height. The benefit-risk ratio of supplementing GH with the weak androgen oxandrolone (Ox) is undefined. Growth hormone were administered (1.33 mg/kg/d) from the age of 8 years-old while estrogens were initiated at the age of 12 years-old. The increase in adult height (adult height minus predicted adult height) and safety factors were evaluated in a systematic manner.